For our editorial planning we use monday.com, a simple and intuitive tool to manage any project or process. Try for free and let us know! 

 

We use monday.com

ScienzaTecnologia

Biocytogen announces acquisition of a third Beacon Optofluidic system to support expanding Antibody Discovery Platform

 BOSTON, Feb. 25, 2021 /PRNewswire/ — Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen’s antibody discovery service platform in the greater Boston area for collaborations across the globe.  Founded on its successful gene editing platform, Biocytogen recently developed humanized immunoglobulin mice that carry the full variable region repertoire (RenMab ™ ), as well as a related common light chain strain, RenLite™. Generation of fully human antibodies in these models minimizes the time required to develop high-affinity antibody therapeutics with favorable pharmacokinetic properties. Biocytogen’s integrative use of Berkeley Lights’ industry-leading light-sorting technology further accelerates the process, due to the rapid screening of thousands of single B cells for antibody hit generation. Together, these technologies allow for the generation and discovery of fully human antibodies in a matter of weeks. About BiocytogenBiocytogen is an international biotechnology company that provides a comprehensive portfolio of products and preclinical services to accelerate new drug discovery and development. Biocytogen’s expertise in gene editing has led to the generation of an extensive catalog of humanized mouse models that have been used to validate antibody drugs undergoing clinical development at its subsidiary, Eucure Biopharma. Biocytogen collaborates with global partners to discover therapeutic antibodies using its flagship RenMab™ model. For more information, please visit https://biocytogen.com/ and click the service brochure. Media Contact:Jenna Frame jframe@biocytogen.com  Logo – https://mma.prnewswire.com/media/1358305/Biocytogen_Logo.jpg     https://www.adnkronos.com/biocytogen-announces-acquisition-of-a-third-beacon-optofluidic-system-to-support-expanding-antibody-discovery-platform_4BZ7OXLeSxhOOZWerumSti

Related posts
DigitaleeconomiafinanzaSviluppo Economico ed InnovazioneTecnologia

Cos’è l’intelligenza digitale? Da ipotesi a Regina delle Soft Skills

Cos’è l’intelligenza digitale?L’intelligenza Digitale è la capacità cognitiva di un…
Read more
Comunicati StampaIntelligenza ArtificialeTecnologia

As voice cloning technology has become ever more effective, it is of increasing interest to actors... and cybercriminals.

When Tim Heller first heard his cloned voice he says it was so accurate that “my jaw hit the…
Read more
Tecnologia

Google e il futuro 'senza cookie', la sfida adv comincia ora

Google cambia, arriva il nuovo core update che richiede aggiustamenti da parte degli operatori del…
Read more

press@comunicatistampa.org

Lascia un commento

Il tuo indirizzo email non sarà pubblicato. I campi obbligatori sono contrassegnati *